Open AccessThis article is
- freely available
Stability of Recombinant Tissue Plasminogen Activator at −30 °C over One Year
College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh 11426, Saudi Arabia
National Guard Health Affairs, King Abdulaziz Medical City, Riyadh, 11426, Saudi Arabia
Received: 12 November 2012; in revised form: 24 December 2012 / Accepted: 26 December 2012 / Published: 2 January 2013
Abstract: Recombinant tissue plasminogen activator (rt-PA) is used to restore patency and avoid inadvertent removal of peripheral and central venous catheters. rt-PA was reconstituted (1 mg/mL) then cryopreserved at −30 °C for 1, 2, 3, 6, 8, and 12 months and, then its stability was determined. After cryopreservation for one and two months, rt-PA kept more than 95% of its activity compared to standard samples, while cryopreservation for three months caused 8% loss of activity. However, after cryopreservation for six months or more, rt-PA retained only 87.5% or less activity compared to standard samples. Therefore, it is recommended that reconstituted rt-PA be cryopreserved at −30 °C for a maximum period of three months.
Keywords: cryopreservation; fibrinolysis; stability; tissue plasminogen activator
Citations to this Article
Cite This Article
MDPI and ACS Style
Alkatheri, A. Stability of Recombinant Tissue Plasminogen Activator at −30 °C over One Year. Pharmaceuticals 2013, 6, 25-31.
Alkatheri A. Stability of Recombinant Tissue Plasminogen Activator at −30 °C over One Year. Pharmaceuticals. 2013; 6(1):25-31.
Alkatheri, Abdulmalik. 2013. "Stability of Recombinant Tissue Plasminogen Activator at −30 °C over One Year." Pharmaceuticals 6, no. 1: 25-31.